Core Insights - The approval of VELSIPITY® (Argenine Acquimod Tablets) by the NMPA marks a significant milestone for the company in the autoimmune field, providing a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis (UC) who have inadequate response to traditional therapies or biologics [1][2] - The company aims to commercialize VELSIPITY® quickly and is actively working to include it in the national medical insurance directory, aligning with its 2030 development strategy focused on dual-driven growth through BD collaboration and self-research [2][4] Group 1: Product and Clinical Research - VELSIPITY® is a next-generation high-selectivity sphingosine-1-phosphate (S1P) receptor modulator, administered once daily, demonstrating rapid onset and strong mucosal healing with good safety characteristics [1] - The approval is based on results from the largest Asian Phase III registration clinical study (ENLIGHTUC) involving 340 patients, as well as global Phase III studies (ELEVATEUC52 and ELEVATEUC12) that confirmed the drug's favorable benefit-risk profile [1][2] Group 2: Commercialization Strategy - The company has established a commercialization platform with three products and is focused on building a comprehensive commercialization system and drug lifecycle management capabilities [3] - Revenue targets include exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030, with an expected compound annual growth rate of over 50% from 2025 to 2030 [3] Group 3: Future Growth and Strategic Goals - The 2030 development strategy emphasizes a dual-driven approach of BD collaboration and self-research, aiming to introduce 3 to 5 late-stage blockbuster products annually and achieve peak sales within three years post-reimbursement [4] - The company plans to introduce over 20 high-value assets by 2030, contributing approximately 6 billion RMB in revenue, with a long-term goal of reaching around 30 billion RMB by 2035 [4]

Core Insights - The approval of Velsipity (Arginine Acumod Tablets) by the NMPA marks a significant milestone for the company in establishing its leading position in the autoimmune field [1][3] - Velsipity is a new generation high-selectivity S1P receptor modulator that offers a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis [2] - The company aims to commercialize Velsipity quickly and push for its inclusion in the national medical insurance directory as part of its 2030 development strategy [3] Clinical Research - The approval is based on results from the ENLIGHT UC study, the largest Phase III registration clinical trial for moderate to severe active ulcerative colitis patients in Asia, involving 340 patients [2] - Velsipity demonstrated statistical significance and clinical relevance in all primary and secondary efficacy endpoints during the 12-week induction and 40-week maintenance treatment periods [2] - The ELEVATE UC Phase III studies further validated Velsipity's favorable benefit-risk profile [2] Commercialization Strategy - The company has laid out plans to establish a comprehensive commercialization system and aims to achieve revenue exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030 [4] - The revenue growth rate is projected to exceed 50% from 2025 to 2030, with a target of maintaining over 15% growth post-2030 [4] - The number of commercialized products is expected to increase to over 20, including Velsipity and other key products [4] Future Development Plans - The 2030 development strategy signifies a crucial milestone for the company in advancing towards the forefront of global biopharmaceuticals [5] - The company plans to introduce 3 to 5 late-stage blockbuster products annually and aims to contribute 6 billion RMB in revenue from over 20 high-value assets by 2030 [5] - The strategic focus will be on maintaining leadership in core therapeutic areas and innovative drug development, aiming to become a leading comprehensive biopharmaceutical company globally [5]